ClinicalTrials.gg
RecruitingNCT05263960Updated May 4, 2025

A Study of CM350 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of CM350 group1 and CM350 group2 in Advanced Solid Tumor, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
248
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open label, dose escalation and expansion Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of CM350 in patients with advanced solid tumors.

The phase I study consists of a dose escalation phase and a dose expansion phase The safety and tolerability of CM350 and the maximum tolerated dose (MTD) (if applicable) will be evaluated in dose escalation phase.

The recommended phase 2 dose (RP2D) of CM350 will be determined in dose expansion phase.

The phase II study is to evaluate the efficacy of CM350 at the recommended phase 2 dose (RP2D) for advanced glypican-3 (GPC3)-positive solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with or cytologically confirmed advanced solid tumors that is to or intolerable with standard treatment, or for which no standard treatment is available.
  • hepatocellular-cancer(HCC) participants must have a Barcelona Clinic Liver Cancer (BCLC) stage of B (ineligible for liver surgery and/or other locoregional treatments, or disease progression after locoregional therapy) or stage C , or a China National Liver Cancer (CNLC) stage of IIb or III (ineligible for liver surgery and/or other locoregional treatments, or disease progression after locoregional therapy).
  • HCC participants must have a score of ≤7.
  • Phase I dose escalation phase: participants must have evaluable lesions based on version 1.1.Phase I dose expansion phase and phase II: participants must have at least one .
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received any cytotoxic chemotherapy, radiotherapy, biological therapy (oncologic vaccines, cytokines, or growth factors for cancer control), or any other anticancer drug treatment (defined as treatments without regulatory approval for any indication) within 28 days before the first dose of CM350.

Note: For palliative radiotherapy to non-central nervous system lesions (total radiotherapy duration ≤14 days) to improve symptoms, a minimum of 7 days before the first dose is required.

  • Patients who have received any immunotherapy (including but not limited to , PD-L1, anti-cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], chimeric antigen receptor T-cell [CAR-T] therapy, etc.) within 28 days or 5 half-lives (whichever is shorter) before the first dose of CM350.
  • Patients who have received targeted therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of CM350.
  • Patients who have previously received any therapy targeting GPC3, including but not limited to monoclonal antibodies, peptide vaccines, CAR-T, and bispecific antibodies.
  • Received chronic systemic therapy (daily intake of more than 10 mg prednisone or equivalent doses of other corticosteroids) or any other form of treatment within 7 days before the first dose of CM350.
  • Known active central nervous system . Note: Participants with previously treated that have been stable for at least 14 days before the first dose (confirmed by repeat imaging at least 4 weeks apart, with the repeat imaging conducted during the screening period) may be considered for enrollment.
  • Participants with uncontrolled pleural effusion, ascites, or pericardial effusion as assessed by the investigator.
  • History of other within 5 years before the first dose of CM350, excluding cured basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, or ductal carcinoma in situ of the breast.
  • Presence of active infection at screening as assessed by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Dose escalation phase in phase I

    There are 11 target dose levels in dose escalation phase.

    Biological: CM350 group1

  • Experimental
    Dose expansion phase in phase I

    Three or four doses will be selected for further evaluation in dose expansion phase to determine the RP2D (recommended phase 2 dose).

    Biological: CM350 group2

  • Experimental
    Phase II

    The efficacy of CM350 will be evaluated at RP2D (recommended phase 2 dose) for advanced GPC3-positive solid tumors.

    Biological: CM350 group3

Interventions

  • BiologicalCM350 group1

    CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).

  • BiologicalCM350 group2

    CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).

  • BiologicalCM350 group3

    CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).

06

What researchers measure

Primary outcomes

  1. Dose escalation phase in phase I:Incidence of Adverse events(AEs), including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Incidence of Adverse events(AEs), including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: Up to 5 years

  2. Dose escalation phase in phase I:Dose-Limiting Toxicity (DLT).

    Dose-Limiting Toxicity (DLT).

    Time frame: Up to 7 days after the first target dose

  3. Dose escalation phase in phase I:Maximum tolerated dose (MTD) (if applicable).

    Maximum tolerated dose (MTD) (if applicable).

    Time frame: Up to the end of dose escalation phase (3 years)

  4. Dose expansion phase in phase I:To determine the recommended Phase 2 Dose (RP2D).

    the efficacy including objective response rate (ORR), disease control rate (DCR), etc., safety, pharmacokinetics (PK) and pharmacodynamics (PD) profile of CM350 will be assessed.

    Time frame: Up to 5 years

  5. Phase II:To evaluate the efficacy of CM350 in advanced glypican-3-positive solid tumors.

    including objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Modified Response Evaluation Criteria in Solid Tumors \[mRECIST\] for liver cancer and RECIST v1.1) evaluated by investigator.

    Time frame: Up to 5 years

Secondary outcomes

  1. Phase I & Phase II: Area Under the Curve from 0 to the time of the last quantifiable concentration (AUC0-t).

    After first and multiple dosing

    Time frame: Up to 5 years

  2. Phase I & Phase II: To assess the incidence of anti-drug antibody (ADA).

    To assess the incidence of anti-drug antibody (ADA)

    Time frame: Up to 5 years

  3. Phase I: To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for liver cancer and RECIST v1.1].

    To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 \[Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for liver cancer and RECIST v1.1\]

    Time frame: Up to 5 years

  4. Phase I & Phase II: To evaluate the duration of response (DOR) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1).

    To evaluate the duration of response (DOR) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1)

    Time frame: Up to 5 years

  5. Phase I & Phase II: To evaluate the disease control rate (DCR) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1).

    To evaluate the disease control rate (DCR) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1)

    Time frame: Up to 5 years

  6. Phase I & Phase II:To evaluate the time to response (TTR) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1.

    To evaluate the time to response (TTR) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1

    Time frame: Up to 5 years

  7. Phase I & Phase II:To evaluate the time to progression (TTP) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1).

    To evaluate the time to progression (TTP) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1)

    Time frame: Up to 5 years

  8. Phase I & Phase II:To evaluate the progression-free survival (PFS) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1).

    To evaluate the progression-free survival (PFS) per RECIST v1.1(mRECIST for liver cancer and RECIST v1.1)

    Time frame: Up to 5 years

  9. Phase I & Phase II:To evaluate the overall survival (OS)

    To evaluate the overall survival (OS)

    Time frame: Up to 5 years

  10. Phase I & Phase II:To assess the cytokine interleukin-2 (IL-2).

    To assess the pharmacokinetic (PD) profile of CM350.

    Time frame: Up to 5 years

  11. Phase II:Incidence of Adverse events(AEs), including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Incidence of Adverse events(AEs), including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: Up to 5 years

  12. Phase I & Phase II:Area Under the Curve over a dosing interval (AUC tau).

    Area Under the Curve over a dosing interval (AUC tau).

    Time frame: Up to 5 years

  13. Phase I & Phase II:Peak Plasma Concentration (Cmax).

    Peak Plasma Concentration (Cmax)

    Time frame: Up to 5 years

  14. Phase I & Phase II:Time of Maximum Observed Concentration (Tmax).

    Time of Maximum Observed Concentration (Tmax)

    Time frame: Up to 5 years

  15. Phase I & Phase II:Observed concentration at the end of a dosing interval (Ctrough).

    Observed concentration at the end of a dosing interval (Ctrough)

    Time frame: Up to 5 years

  16. Phase I & Phase II:To assess the cytokine interleukin-6 (IL-6).

    To assess the cytokine interleukin-6 (IL-6)

    Time frame: Up to 5 years

  17. Phase I & Phase II:To assess the cytokine interleukin-10 (IL-10).

    To assess the cytokine interleukin-10 (IL-10)

    Time frame: Up to 5 years

  18. Phase I & Phase II:To assess the cytokine interferon-gamma(IFN-γ).

    To assess the cytokine interferon-gamma(IFN-γ)

    Time frame: Up to 5 years

  19. Phase I & Phase II:To assess the cytokine tumor necrosis factor-alpha (TNF-α).

    To assess the cytokine tumor necrosis factor-alpha (TNF-α)

    Time frame: Up to 5 years

  20. Phase I & Phase II: To assess the Immunophenotyping cluster of differentiation 3 positive (CD3+).

    To assess the Immunophenotyping cluster of differentiation 3 positive (CD3+).

    Time frame: Up to 5 years

  21. Phase I & Phase II: To assess the Immunophenotyping cluster of differentiation 4 positive (CD4+).

    To assess the Immunophenotyping cluster of differentiation 4 positive (CD4+).

    Time frame: Up to 5 years

  22. Phase I & Phase II: To assess the Immunophenotyping cluster of differentiation 8 positive (CD8+).

    To assess the Immunophenotyping cluster of differentiation 8 positive (CD8+).

    Time frame: Up to 5 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Mar 3, 2022
StartActual
Apr 21, 2022
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05263960
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Apr 21, 2022
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 4, 2025

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
+862888610620
Jia Fan
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion